Tissue Regenix Group PLC (TRX.L) Quote| Reuters.com
Edition:
United States

Tissue Regenix Group PLC (TRX.L)

TRX.L on London Stock Exchange

18.00GBp
8:54am EDT
Change (% chg)

1.25p (+7.46%)
Prev Close
16.75p
Open
17.50p
Day's High
--
Day's Low
--
Volume
475,571
Avg. Vol
724,697
52-wk High
22.50p
52-wk Low
12.70p

TRX.L

Chart for TRX.L

About

Tissue Regenix Group plc is a United Kingdom-based medical devices company. The Company is principally engaged in the exploitation of platform technologies in the field of tissue engineering and regenerative medicine. The Company has developed decellularisation (dCELL) technology, which removes DNA and other cellular material... (more)

Overall

Beta: 1.07
Market Cap(Mil.): £127.32
Shares Outstanding(Mil.): 760.12
Dividend: --
Yield (%): --

Financials

  TRX.L Industry Sector
P/E (TTM): -- 42.29 36.15
EPS (TTM): -0.01 -- --
ROI: -57.76 -6.23 14.31
ROE: -57.20 -5.61 15.51

BRIEF-Tissue Regenix granted 510k market clearance from FDA for SurgiPure XD

* Granted 510k market clearance from food and drug administration for surgipure xd

Mar 09 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : Wright Reports
$75.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.